Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH3 | Q9Y5N1 | 12/20 | 0.53 |
| ▸ | P2RX3 | P56373 | 1/20 | 0.46 |
| ▸ | PIM1 | P11309 | 1/20 | 0.42 |
| ▸ | KCNH2 | Q12809 | 6/20 | 0.40 |
| ▸ | CCKBR | P32239 | 1/20 | 0.39 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6769372 | 0.87 | P2RX3 (0.46) | HRH3P2RX3PIM1KCNH2EPHX2 | |
| SCHEMBL12442660 | 0.87 | HRH3 (0.52) | HRH3P2RX3PIM1KCNH2EPHX2 | |
| SCHEMBL29523531 | 0.87 | HRH3 (0.52) | HRH3P2RX3PIM1KCNH2EPHX2 | |
| SCHEMBL27483408 | 0.87 | P2RX3 (0.57) | HRH3P2RX3PIM1KCNH2 | |
| SCHEMBL6769375 | 0.87 | P2RX3 (0.46) | HRH3P2RX3PIM1KCNH2EPHX2 | |
| SCHEMBL8342318 | 0.87 | P2RX3 (0.57) | HRH3P2RX3PIM1KCNH2 | |
| SCHEMBL23260557 | 0.87 | HRH3 (0.50) | HRH3P2RX3PIM1 | |
| SCHEMBL951361 | 0.87 | HRH3 (0.50) | HRH3P2RX3PIM1 | |
| SCHEMBL950955 | 0.87 | HRH3 (0.50) | HRH3P2RX3PIM1 | |
| SCHEMBL3961763 | 0.87 | HRH3 (0.50) | HRH3P2RX3PIM1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4216946-A1 | PHARMACEUTICAL COMPOUNDS FOR THE TREATMENT OF COMPLEMENT MEDIATED DISORDERS | Achillion Pharmaceuticals, Inc. (US) | 2023-08-02 | — | — | EP | disclosed |
| CN-116437913-A | Pharmaceutical compounds for treating complement-mediated disorders | 艾其林医药公司 | 2023-07-14 | — | — | CN | disclosed |
| WO-2022066774-A1 | PHARMACEUTICAL COMPOUNDS FOR THE TREATMENT OF COMPLEMENT MEDIATED DISORDERS | ACHILLION PHARMACEUTICALS, INC. (US) | 2022-03-31 | — | — | WO | disclosed |